InterMune Earnings Conference Call (Q4 2012)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Feb 21 Calls Today's Calls

Call Details InterMune Earnings Conference Call (Q4 2012) Scheduled to start Thu, Feb 21, 2013, 4:30 pm Eastern -- this event is ongoing now-- Listen to the ongoing live event audio stream About InterMune Inc (NasdaqGS:ITMN) Other Calls  InterMune, Inc., a biotech company, focuses on developing and commercializing therapies in pulmonology and hepatology primarily in the United States and Europe. The company primarily offers Actimmune for the treatment of patients with severe, malignant osteopetrosis, and chronic granulomatous disease. Its pulmonology product portfolio includes lead product candidate, pirfenidone, a phase III product being developed for the treatment of patients with idiopathic pulmonary fibrosis; and a research program focused on small molecules for pulmonary diseases. The company’s hepatology portfolio comprises the HCV protease inhibitor RG7227, a phase IIb chronic hepatitis C program and an early stage research program evaluating a new target in hepatology. It has license and collaboration agreements with Hoffmann-LaRoche Inc. and F. Hoffmann-LaRoche Ltd.; Genentech, Inc.; Boehringer Ingelheim International GmbH; Connetics Corporation; and Novartis Corporation. The company was founded in 1998 and is headquartered in Brisbane, California. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings